Stock GNRO GENEURO SA
Add to a list
To use this feature you must be a member
Log inSign up

GeNeuro SA

Equities

GNRO

CH0308403085

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 11:37:56 2024-04-23 am EDT 		5-day change 1st Jan Change
1.43 EUR -0.35% Intraday chart for GeNeuro SA -0.69% +31.19%
Mar. 20 Geneuro SA Announces Appointments of Board of Directors CI
Feb. 02 GeNeuro: share price falls after private placement CF

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about GeNeuro SA

Geneuro SA Announces Appointments of Board of Directors CI
GeNeuro: share price falls after private placement CF
GeNeuro Raises EUR5 Million from Share Issue MT
GeNeuro appoints new Chief Medical Officer CF
Geneuro Sa Announces Executive Changes CI
GeNeuro: Citigroup Global Markets Ltd crosses the 5% threshold CF
GeNeuro: positive opinion for continuation of trial CF
GeNeuro's Mid-stage Study for Post-COVID Symptoms Therapy Gets Medical Committee's Nod MT
Geneuro S.A. Recommends Continuing the Trial Evaluating Temelimab in Long Covid Without Modifications CI
GeNeuro Finalizes Patient Enrollment in Early-stage Trial of Long-COVID Treatment MT
GeNeuro: end of recruitment for Covid long trial CF
GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024 CI
GeNeuro and Verily Collaborate to Advance Long-COVID Research CI
GeNeuro SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
GeNeuro in Collaboration with Heinrich-Heine University Announce Publication in PNAS of Results from their Joint Research on Role of HERV-W in MS CI
GeNeuro SA Announces Recent Study Demonstrates the Strong Link Between SARS-CoV-2 Infection and HERV-W Activation in Hospitalized Psychotic Patients CI
GeNeuro SA Reports Earnings Results for the Full Year Ended December 31, 2022 CI
GeNeuro Lands EUR25 Million Loan to Advance Long COVID-19 Trial MT
GeNeuro Begins Recruitment for Trial to Assess Temelimab's Efficacy as Therapy for Long COVID-19 MT
GeNeuro SA Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-Covid Assessing Temelimab CI
Geneuro’S Protect-Ms Phase 2 Trial Data, Presented At the Ectrims 2022 Congress in Amsterdam, Confirms Synergistic Neuroprotective Potential of Temelimab in Ms CI
GeNeuro Will Present Phase IIb Safety and Efficacy Data on Temelimab from its ProTEct-MS Study at the 38thCongress of the European Committee for Treatment and Research in Multiple Sclerosis CI
GeNeuro SA Reports Earnings Results for the Half Year Ended June 30, 2022 CI
GeNeuro SA Announces Two Studies on ALS Published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein and the Rationale for Targeted Therapy with Specific Antibody CI
GeNeuro Unit Becomes R&D Partner In EU-funded Precision Medicine Project MT

Chart GeNeuro SA

Chart GeNeuro SA
More charts

Company Profile

GeNeuro SA specializes in the development of safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis or type 1 diabetes by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. A new frontier pioneered by GeNeuro SA since 2006 and based on research by Institut Mérieux and INSERM.
Sector
Biotechnology & Medical Research
Calendar
2024-04-28 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.43 EUR
Average target price
4 EUR
Spread / Average Target
+179.72%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GENEURO SA Stock GeNeuro SA
+31.19% 45.28M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+3.13% 43.43B
LONZA GROUP AG Stock Lonza Group AG
+48.83% 41.69B
MODERNA, INC. Stock Moderna, Inc.
+8.49% 41.31B
CELLTRION, INC. Stock Celltrion, Inc.
-10.82% 27.14B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.26% 25.28B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.69% 18.47B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+1.58% 12.33B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.83% 12.59B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.63% 11.03B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GNRO Stock
  4. News GeNeuro SA
  5. GeNeuro Concludes $8 Million Capital Raise to Complete Post-COVID Clinical Program